M IJ Ų

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Campbell Rogers, Elazer R. Edelman, and Daniel I. Simon

Serial No.:

Continuation of 08/823,999

Express Mail Label No.: EL 709 418 819 US

Date of Deposit:

February 7, 2001

Filed:

February 7, 2001

For:

MODULATION OF VASCULAR HEALING BY INHIBITION

OF LEUKOCYTE ADHESION AND FUNCTION

BOX PATENT APPLICATION **Assistant Commissioner for Patents** Washington, D.C. 20231

REQUEST FOR FILING A CONTINUATION APPLICATION UNDER 37 C.F.R. § 1.53(b)

Sir:

This is a request for filing a continuation application under 37 C.F.R. § 1.53(b), of copending prior application U.S.S.N. 08/823,999 filed March 25, 1997, entitled 'Modulation of Vascular Healing by Inhibition of Leukocyte Adhesion and Function", by Campbell Rogers, Elazer R. Edelman, and Daniel I. Simon. The application includes 1 page of abstract, 24 pages of specification, 3 pages of claims, 3 sheets of formal drawings, and a copy of the executed Declaration for Patent Application from prior application U.S.S.N. 08/823,999.

A Preliminary Amendment and an Information Disclosure Statement are enclosed.

Also enclosed from prior application U.S.S.N. 08/823,999 are copies of the (1) executed Assignment from Campbell Rogers and Elazer R. Edelman to Massachusetts Institute of Technology, recorded on May 27, 1997, at Reel 8640, Frame 0041; (2) executed Assignment from Daniel I. Simon to Brigham and Women's Hospital, Inc., recorded on May 27, 1997, at

The state of the s

ij

LA LA CA CA

Continuation of U.S.S.N. 08/823,999

Filed: February 7, 2001

REQUEST FOR FILING A CONTINUATION

APPLICATION UNDER 37 C.F.R. § 1.53(b) Express Mail Label No.: EL 709 418 819 US

Date of Deposit: February 7, 2001

Reel 8640, Frame 0123; (3) executed Certificate Under 37 C.F.R. § 3.73(b) by Massachusetts

Institute of Technology; and (4) executed Certificate Under 37 C.F.R. § 3.73(b) by Brigham and

Women's Hospital, Inc.

Pursuant to 37 C.F.R. § 1.63(d), the copy of the executed Declaration included in the

new application is a copy of the executed Declaration filed in parent application Serial

No. 08/823,999, to which the new application claims benefit.

This application contains nucleic acid and/or protein sequences as defined in 37 C.F.R.

§§ 1.821-1.825. The sequence listing for the new application is identical to the sequence listing

for the parent application Serial No. 08/823,999 filed March 25, 1997, by Campbell Rogers,

Elazer R. Edelman, and Daniel I. Simon. A sequence listing in computer readable form was

submitted May 24, 1999, in Application Serial No. 08/823,999 filed March 25, 1997.

No subsequent sequence listing was submitted.

Pursuant to 37 C.F.R. § 1.821(e), applicants hereby request that the computer readable

form of the sequence listing submitted in application Serial No. 08/823,999 be used as the

computer readable form of the sequence listing for the new application.

I declare that the material on the diskette is identical to the paper copy of the Sequence

Listing present in the above-identified parent application, and that all statements made on

information and belief are believed to be true and further that these statements were made with

the knowledge that willful false statements may jeopardize the validity of the application or any

patent issuing thereon.

2

1320641v1

MIT 7501 CON (BWH 0389) 20220/391 Continuation of U.S.S.N. 08/823,999

Filed: February 7, 2001

REQUEST FOR FILING A CONTINUATION

APPLICATION UNDER 37 C.F.R. § 1.53(b) Express Mail Label No.: EL 709 418 819 US

Date of Deposit: February 7, 2001

This application is entitled to small entity status pursuant to 37 C.F.R. § 1.27.

Submitted with the new application are a (1) check in the amount of \$355.00 to cover the filing fee for a small entity; (2) Fee Transmittal (PTO/SB/17); and (3) Utility Patent Application Transmittal (PTO/SB/45). It is believed that \$355.00 is the proper filing fee for a small entity, as the application includes 2 independent claim and a total of 17 claims after entry of the enclosed Preliminary Amendment.

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 01-2507. To facilitate this process, applicants have enclosed a duplicate of this letter.

The power of attorney in the prior application is to Patrea L. Pabst, Registration No. 31,284.

This application is being filed on February 7, 2001, by mailing the application to Box Patent Application, Assistant Commissioner of Patents, Washington, D.C. 20231 via the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 C.F.R. § 1.10. The Express Mail Label Number appears in the heading of this paper which is attached to the application papers pursuant to 37 C.F.R. § 1.10(b).

Continuation of U.S.S.N. 08/823,999

Filed: February 7, 2001

REQUEST FOR FILING A CONTINUATION APPLICATION UNDER 37 C.F.R. § 1.53(b) Express Mail Label No.: EL 709 418 819 US

Date of Deposit: February 7, 2001

All correspondence concerning this application should be mailed to:

Patrea L. Pabst, Esq. ARNALL GOLDEN & GREGORY, LLP 2800 One Atlantic Center 1201 West Peachtree Street Atlanta, GA 30309-3450

Respectfully submitted,

Patrea L. Pabst

Reg. No. 31,284

Date: February 7, 2001

ARNALL, GOLDEN & GREGORY, LLP 2800 One Atlantic Center 1201 West Peachtree Street Atlanta, Georgia 30309-3450 (404) 873-8794 (404) 873-8795 (fax)